Emyria Gains Ethics Endorsement for Psilocybin Program

Emyria is pleased to announce that its lead psychiatrists have received endorsement from the ACT Health Ethics Committee for the Company's psilocybin-assisted therapy program - aiming to provide long-term improvements for patients with treatment-resistant depression - and complementing Emyria's existing MDMA-assisted therapy programs. The final approval is pending from Australia's Therapeutic Goods Administration, expected within the next month. By expanding into psilocybin-assisted therapy, Emyria is enhancing its capacity to offer innovative mental health treatments directly to eligible patients under the TGA's framework. Recent research has highlighted psilocybin's potential in treating treatment-resistant depression and this strategic move aligns with Emyria's mission to maximise patient outcomes and continuously improve treatment protocols through data-driven approaches. Investors are encouraged to engage with Emyria for further information on this development and investment opportunities. Feel free to reach out with any questions or inquiries as we continue to drive impactful outcomes in mental health treatment.